Inventor · disambiguated record
Gregory R. Bluemling
Also filed as: BLUEMLING GREGORY · BLUEMLING GREGORY R
14 granted patents·10 pending applications·27 citations·filing 2014–2024
89Inventor score
Files withUNIV EMORY24
Top patents by PatentIndex Score
24 records- 0193US11981699B2Phosphoramidates for the treatment of hepatitis B virusUNIV EMORY·Filed 2021·Granted May 14, 2024·2 cites·12 claims
- 0292US11331331B2N4-hydroxycytidine and derivatives and anti-viral uses related theretoUNIV EMORY·Filed 2018·Granted May 17, 2022·4 cites·10 claims
- 0388US10683319B2Phosphoramidates for the treatment of hepatitis B virusUNIV EMORY·Filed 2015·Granted Jun 16, 2020·4 cites·8 claims
- 0487US12414961B2Substituted nucleosides and nucleotides for treating viral infectionsUNIV EMORY·Filed 2023·Granted Sep 16, 2025·0 cites·15 claims
- 0585US12329770B2N4-hydroxycytidine and derivatives and anti-viral uses related theretoUNIV EMORY·Filed 2023·Granted Jun 17, 2025·0 cites·11 claims
- 0685US10874683B2N4-hydroxycytidine and derivatives and anti-viral uses related theretoUNIV EMORY·Filed 2017·Granted Dec 29, 2020·6 cites·16 claims
- 0785US10149859B2Nucleotide and nucleoside therapeutic compositions and uses related theretoUNIV EMORY·Filed 2014·Granted Dec 11, 2018·6 cites·14 claims
- 0884US11364257B2Phosphoramidates for the treatment of hepatitis B virusUNIV EMORY·Filed 2017·Granted Jun 21, 2022·2 cites·18 claims
- 0984US11166973B2Substituted nucleotides and nucleosides for treating viral infectionsUNIV EMORY·Filed 2018·Granted Nov 9, 2021·2 cites·12 claims
- 1075US11857560B2Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infectionsUNIV EMORY·Filed 2021·Granted Jan 2, 2024·0 cites·21 claims
- 1173US11903959B2N4-hydroxycytidine and derivatives and anti-viral uses related theretoUNIV EMORY·Filed 2021·Granted Feb 20, 2024·0 cites·8 claims
- 1271US11447518B2Phosphoramidates for the treatment of hepatitis B virusUNIV EMORY·Filed 2020·Granted Sep 20, 2022·0 cites·14 claims
- 1370US2025064844A1N4-hydroxycytidine and derivatives and anti-viral uses related theretoUNIV EMORY·Filed 2024·Application pending·0 cites
- 1469US11628181B2N4-hydroxycytidine and derivatives and anti-viral uses related theretoUNIV EMORY·Filed 2020·Granted Apr 18, 2023·0 cites·25 claims
- 1569US2024180948A14'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related theretoUNIV EMORY·Filed 2023·Application pending·0 cites
- 1668US11192914B2Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related theretoUNIV EMORY·Filed 2017·Granted Dec 7, 2021·1 cites·18 claims
- 1767US2022280542A1Phosphoramidates for the treatment of hepatitis b virusUNIV EMORY·Filed 2022·Application pending·0 cites
- 1863US2023062181A1Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related theretoUNIV EMORY·Filed 2021·Application pending·0 cites
- 1956US2025281519A1Nucleotide and nucleoside therapeutic compositions, combinations and uses related theretoUNIV EMORY·Filed 2022·Application pending·0 cites
- 2056US2021252033A1N4-hydroxycytidine and derivatives and anti-viral uses related theretoUNIV EMORY·Filed 2021·Application pending·0 cites
- 2150US2021308168A14'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related theretoUNIV EMORY·Filed 2019·Application pending·0 cites
- 2248US2019022116A1N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related TheretoUNIV EMORY·Filed 2015·Application pending·0 cites
- 2347US2024165143A14'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related theretoUNIV EMORY·Filed 2020·Application pending·0 cites
- 2435US2019085013A1Nucleotide and nucleoside therapeutic compositions and uses related theretoUNIV EMORY·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gregory R. Bluemling files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →